Page last updated: 2024-10-30

methazolamide and Huntington Disease

methazolamide has been researched along with Huntington Disease in 1 studies

Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, X1
Zhu, S1
Pei, Z1
Drozda, M1
Stavrovskaya, IG1
Del Signore, SJ1
Cormier, K1
Shimony, EM1
Wang, H1
Ferrante, RJ1
Kristal, BS1
Friedlander, RM1

Other Studies

1 other study available for methazolamide and Huntington Disease

ArticleYear
Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008, Sep-17, Volume: 28, Issue:38

    Topics: Animals; Brain; Carbonic Anhydrase Inhibitors; Caspases; Cell Death; Cell Line, Transformed; Cytochr

2008